First case report of acute generalized exanthematous pustulosis (AGEP) caused by gadolinium confirmed by patch testing

2018 ◽  
Vol 78 (2) ◽  
pp. 166-168 ◽  
Author(s):  
M. Teresa Bordel Gómez ◽  
Cristina Martín García ◽  
Carmen Meseguer Yebra ◽  
M. Isabel Zafra Cobo ◽  
M. Esther Cardeñoso Álvarez ◽  
...  
Keyword(s):  
Case Report ◽  
Patch Testing ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Exanthematous Pustulosis

Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine: First Case Report in Canada and Review of the Literature

2013 ◽  
Vol 17 (6) ◽  
pp. 414-418 ◽  
Author(s):  
Kristy Bailey ◽  
Daniel Mckee ◽  
Judy Wismer ◽  
Neil Shear
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Drug Eruption ◽  
Spontaneous Resolution ◽  
Review Of The Literature ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Pathologic Findings ◽  
Complicated Course ◽  
Exanthematous Pustulosis

Background: Acute generalized exanthematous pustulosis (AGEP) is a rare drug eruption presenting with an acute, extensive formation of nonfollicular sterile pustules on an erythematous and edematous base. Typically, the rash is accompanied by fever and leukocytosis, with spontaneous resolution in < 15 days. The incidence of AGEP is estimated at one to five cases per million people per year. Only 18% of these are from nonantibiotics. Hydroxychloroquine (HCQ) is an antimalarial agent that is also used to treat various dermatologic and rheumatologic conditions. Objective: We report the first observation in Canada of a patient with AGEP induced by HCQ. Methods and Results: AGEP was diagnosed in a 48-year-old female who had been taking HCQ for 2 weeks and then developed a diffuse erythematous and edematous pustular eruption. Clinical and pathologic findings were consistent with a diagnosis of AGEP. The patient was treated with steroids and supportive measures. The rash resolved after 18 days and a complicated course in hospital. Conclusion: AGEP is a rare drug eruption, usually to antibiotics. We report the first case in Canada of AGEP as an adverse reaction to HCQ. Clinicians should keep in mind the possibility of this severe skin eruption.

First case report of acute generalized exanthematous pustulosis (AGEP) caused by mifepristone

2019 ◽  
Vol 82 (3) ◽  
pp. 177-179 ◽  
Author(s):  
Li Zhang ◽  
Miaohong Qian ◽  
Ling Hong ◽  
Qunxiong Wu
Keyword(s):  
Case Report ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Exanthematous Pustulosis

A Case of Acute Generalized Exanthematous Pustulosis by Cefixime with Oral Mucosal Involvement

2020 ◽  
Vol 15 (3) ◽  
pp. 236-239 ◽  
Author(s):  
Ramanachary Namoju ◽  
Mohammed Ismail ◽  
Vinay Kumar Golla ◽  
Tejaswini Bamini ◽  
Thanmaya Lakshmi Akarapu ◽  
...  
Keyword(s):  
Case Report ◽  
Management Strategies ◽  
Beta Lactam ◽  
Mucosal Membrane ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Cutaneous Adverse Reaction ◽  
Mucosal Involvement ◽  
Lactam Antibiotic ◽  
Exanthematous Pustulosis

Acute generalized exanthematous pustulosis (AGEP) is a rare severe cutaneous adverse reaction characterized by the development of numerous sterile and non-follicular pustules on an erythematous base with no or minimal mucous membrane involvement associated with fever and leucocytosis. Cefixime is a cephalosporin-type beta-lactam antibiotic commonly used for the management of several infections. The Cefixime-induced AGEP cases are known to be rare. Here, we present the case report of a 26-year old female who developed Cefixime-induced AGEP with mucosal membrane involvement. To the best of our knowledge, this is the first case to report the mucosal membrane involvement in Cefixime-induced AGEP. We are presenting this case report to draw the attention on the existence and plethora of symptoms of Cefixime-induced AGEP hoping that the clinicians will reckon these in their differential diagnosis and implement the appropriate management strategies for this rare adverse event in their clinical practice.

First case of acute generalized exanthematous pustulosis caused by pitavastatin: possible pathogenetic role of IL-36

2016 ◽  
Vol 26 (1) ◽  
pp. 106-107 ◽  
Author(s):  
Natsuko Saito-Sasaki ◽  
Yu Sawada ◽  
Shun Ohmori ◽  
Daisuke Omoto ◽  
Sanehito Haruyama ◽  
...  
Keyword(s):  
Pathogenetic Role ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Exanthematous Pustulosis

Acute generalized exanthematous pustulosis due to diltiazem: confirmation by patch testing

1997 ◽  
Vol 137 (5) ◽  
pp. 837-839 ◽  
Author(s):  
J.M. Vicente-Calleja ◽  
A. Aguirre ◽  
N. Landa ◽  
V. Crespo ◽  
R. González-Pérez ◽  
...  
Keyword(s):  
Patch Testing ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Exanthematous Pustulosis

Acute Generalized Exanthematous Pustulosis Induced by Amoxicillin/Clavulanic Acid

2015 ◽  
Vol 19 (6) ◽  
pp. 592-594 ◽  
Author(s):  
Ekaterini Syrigou ◽  
Dimitra Grapsa ◽  
Andriani Charpidou ◽  
Konstantinos Syrigos
Keyword(s):  
Clavulanic Acid ◽  
Patch Testing ◽  
Clinical Presentation ◽  
Drug Induced ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Amoxicillin Clavulanic Acid ◽  
Exanthematous Pustulosis ◽  
Histopathologic Features

Drug-induced acute generalized exanthematous pustulosis is a rare pustular skin reaction, most commonly triggered by antibiotics. Although its diagnosis is based primarily on the presence of specific clinical and histopathologic features, additional in vivo (patch testing) or in vitro testing may be required, especially in atypical cases, to more accurately determine the causative agent. The authors report a histologically confirmed case of acute generalized exanthematous pustulosis that was induced by amoxicillin/clavulanic acid, as documented by subsequent patch testing, and presented with generalized painful lymphadenopathy, mimicking an acute infectious process. This is a very rare and diagnostically challenging clinical presentation of acute generalized exanthematous pustulosis, which has been reported, to the best of our knowledge, only once previously.

Sign in / Sign up

Export Citation Format

Share Document